Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "Prostate cancer" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-15 z 51
Tytuł:
„Iron Heart”: Reversible Cause of Dilated Cardiomyopathy Secondary to Cardiac Toxicity in Elderly Patient with Myelodysplastic Syndrome
Autorzy:
Martin-Garcia, Ana
Alonso Fernandez de Gatta, Marta
Diez-Campelo, María
Martín-García, Agustín C.
Barreiro Pérez, Manuel
Diaz-Pelaez, Elena
López Cadenas, Félix
Sanchez, Pedro L.
Powiązania:
https://bibliotekanauki.pl/articles/1035672.pdf
Data publikacji:
2019
Wydawca:
Medical Education
Tematy:
advanced prostate cancer
androgen depravation therapy
triptorelin
Opis:
Triptorelin as the luteinizing hormone releasing hormone (LHRH) analogue has its own place among other available forms of androgen-depravation therapy (ADT) of locally advanced and metastatic prostate cancer (PCa). Nowadays, in times of development of new therapies in castration-resistant PCa, ADT remains the back bone therapy, which may be supplemented with one of novel drugs. The results of basic research indicate, that apart from the main mechanism of action based on lowering a testosterone concentration to the castration level, triptorelin may have a direct inhibitory effect on tumor cells. Formulations of tryptorelin are available to administer as 1-month, 3-months and 6-months sustained-release forms that may be given intramuscularly or subcutaneously. Constant concentration of triptoreline is maintained by using special microspheres in drug production. Pharmacokinetic and pharmacodynamic properties of particular forms were extensively tested, which allows for safe usage and retain of predictable and high efficacy. Indicators of effective ADT are fast reduction and maintenance of the state of castration. This phenomenon translates into a decrease of the prostate-specific antigen and longer survival. Triptorelin successfully meets these objectives based on a number of phase I–III studies. There is a noticeable lack of comparative studies on effectiveness of particular ADT forms. This may stem from an assumption, that all LHRH analogues demonstrate similar effectiveness because of the class effect. However, some evidence highlight significant differences in efficacy among these drugs. Triptorelin compares especially favourably, particularly as a drug reducing the testosterone level to the lower recommended values (< 20 ng/dl). Side effect profile during the therapy with triptorelin is largely the result of inhibition of the hypothalamic- pituitary-testicular axis. Hormonal disturbances linked to hipoandrogenism cause changes in lipid metabolism and glucose tolerance, which may influence the cardiovascular risk. This article is a review of key reports regarding triptorelin and a summary of the role that triptorelin plays in contemporary ADT in advanced PCa.
Źródło:
OncoReview; 2019, 9, 4; 88-91
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Abiraterone acetate - 10 clinically relevant facts
Autorzy:
Żołnierek, Jakub
Powiązania:
https://bibliotekanauki.pl/articles/2047213.pdf
Data publikacji:
2021-09-30
Wydawca:
Medical Education
Tematy:
prostate cancer
systemic therapy
hormone therapy
abiraterone acetate
Opis:
Prostate cancer is one of the most frequently diagnosed cancers in men. Number of newly diagnosed cases is increasing due to several factors and the most important ones seem to be: population ageing and more sensitive diagnostic procedures. Secondary – the higher efficacy of treatment with its influence on improving patients’ overall survival and the specific mechanism of action of drugs used in systemic therapy lead to growing population of men suffering from prostate cancer in general and, specifically – patients with castration resistance. It is hormone therapy to play the key role in systemic treatment of prostate cancer with increasing significance of novel drugs focused on inhibition of molecular signal transduction mediated by androgen receptor. Abiraterone acetate is the representative of this therapeutic class. The paper describes the most clinically relevant data regarding the drug.
Źródło:
OncoReview; 2021, 11, 3; 80-84
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Analiza kształtu struktur anatomicznych jamy brzusznej dla potrzeb radioterapii nowotworu prostaty
Shape analysis of abdominal structures for prostate radiotherapy process
Autorzy:
Skalski, A.
Łągwa, J.
Kędzierawski, P.
Kukołowicz, P.
Powiązania:
https://bibliotekanauki.pl/articles/156980.pdf
Data publikacji:
2013
Wydawca:
Stowarzyszenie Inżynierów i Techników Mechaników Polskich
Tematy:
segmentacja
radioterapia
nowotwór prostaty
model organu
tomografia komputerowa
analiza obrazów
image segmentation
radiotherapy
prostate cancer
organ model
CT
image analysis
Opis:
W artykule przedstawiono algorytmy opisu kształtu, które mogą zostać wykorzystane do budowy wiedzy a priori, o którą można wzbogacić metody segmentacji danych medycznych. Opisana metodologia została wykorzystana do analizy kształtu struktur anatomicznych okolicy miednicy. Przeprowadzona analiza pozwoliła sprawdzić zmienność geometrii struktur anatomicznych istotnych z punktu widzenia radioterapii nowotworu prostaty, Zmienność kształtu organów oceniono zarówno: pomiędzy osobami w populacji chorych z nowotworem gruczołu krokowego jak i zmienność tych kształtów podczas procesu radioterapeutycznego u pacjenta.
Prostate cancer is one of most frequently diagnosed cancer diseases among men population, especially in Europe and the USA. The number of fatal cases is also significant. It leads to many attempts to improve processes of the cancer diagnosis and therapy. One of most promising methods of treatment is radiation therapy. However, its proper planning requires contouring of every important structure on every slice obtained from the imaging equipment (in example a CT scanner), which is time-consuming for medical staff. To solve this problem, many efforts are made to construct algorithms of automatic segmentation of organs in 3D data. To provide the expected efficiency of such methods, a base of a priori knowledge about organs to be delineated is desired. In this paper we present shape description algorithms which could be used to collect the a priori knowledge, potentially able to improve the medical data segmentation methods. The described methodology was used in shape analysis of pelvic region structures, important for planning the prostate cancer radiation therapy, which included: GTV (Gross Tumor Volume), rectum, bladder and femoral heads. In this paper 5 different algorithms are presented. The first proposed method describes the shape of the analyzed organ with parameters (semi-axis lengths) of minimum-volume ellipsoid circumscribed on the structure. The other algorithms provide the information about the shape of the analyzedstructure as a distribution of chosen geometric quantity values (such as distance) between the groups of points randomly selected on its surface. The proposed algorithms were tested on the organ models reconstructed from the structures contoured on the images obtained from CT. As a result of the performed analysis, geometrical variability of the considered structures were specified. Variability of shapes of the analyzed organs was examined for the patients from the population group of men with diagnosed prostate cancer as well as for the single patient cases during radiation therapy.
Źródło:
Pomiary Automatyka Kontrola; 2013, R. 59, nr 3, 3; 254-257
0032-4140
Pojawia się w:
Pomiary Automatyka Kontrola
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Anticancer activity of some polyamine derivatives on human prostate and breast cancer cell lines
Autorzy:
Szumilak, Marta
Galdyszynska, Malgorzata
Dominska, Kamila
Stanczak, Andrzej
Piastowska-Ciesielska, Agnieszka
Powiązania:
https://bibliotekanauki.pl/articles/1038652.pdf
Data publikacji:
2017
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
polyamine derivatives
prostate cancer
breast cancer
mitochondrial potential
cell cycle
apoptosis
Opis:
The aim of this study was to expand our knowledge about anticancer activity of some polyamine derivatives with quinoline or chromane as terminal moieties. Tested compounds were evaluated in vitro towards metastatic human prostate adenocarcinoma (PC3), human carcinoma (DU145) and mammary gland adenocarcinoma (MCF7) cell lines. Cell viability was estimated on the basis of mitochondrial metabolic activity using water-soluble tetrazolium WST1 to establish effective concentrations of the tested compounds under experimental conditions. Cytotoxic potential of polyamine derivatives was determined by the measurement of lactate dehydrogenase activity released from damaged cells, changes in mitochondrial membrane potential, the cell cycle distribution analysis and apoptosis assay. It was revealed that the tested polyamine derivatives differed markedly in their antiproliferative activity. Bischromane derivative 5a exhibited a rather cytostatic than cytotoxic effect on the tested cells, whereas quinoline derivative 3a caused changes in cell membrane integrity, inhibited cell cycle progression, as well as induced apoptosis of prostate and breast cancer cells which suggest its potential application in cancer therapy.
Źródło:
Acta Biochimica Polonica; 2017, 64, 2; 307-313
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Apalutamid for treatment of nonmetastatic castration-resistant prostate cancer - case study
Autorzy:
Sikora-Kupis, Bożena
Powiązania:
https://bibliotekanauki.pl/articles/22676707.pdf
Data publikacji:
2023-03-31
Wydawca:
Medical Education
Tematy:
non-metastatic castration-resistant prostate cancer
nmCRPC
androgen receptor targeted agents
ARTA
apalutamide
darolutamide
enzalutamide
Opis:
A special form of prostate cancer is non-metastatic castration-resistant prostate cancer. Patients with this form have rising prostate-specific antigen and castrate testosterone levels, with no radiological findings of metastatic disease on computed tomography and bone scan. The phase III trials demonstrated apalutamide, darolutamide or enzalutamide to be associated with a significantly longer median metastasis-free survival. The featured description presents one case of man with non-metastatic castration-resistant prostate cancer who was treated with apalutamide.
Źródło:
OncoReview; 2023, 13, 1; 6-8
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Apalutamide - 10 clinically important facts
Autorzy:
Juszczak, Kajetan
Drewa, Tomasz
Powiązania:
https://bibliotekanauki.pl/articles/2047224.pdf
Data publikacji:
2021-09-30
Wydawca:
Medical Education
Tematy:
apalutamide
prostate cancer
nonmetastatic
metastatic
CRPC
CSPC
Opis:
Apalutamide belongs to the ARTA group. This drug is a new generation selective androgen receptor inhibitor. Patients with prostate cancer develop resistance to castration testosterone levels over time during hormone therapy. Therefore, it is necessary to consider additional therapeutic options based on drugs from the ARTA group. Apalutamide is used in the treatment of patients with non-metastatic as well as metastatic prostate cancer. This article presents the most important clinical facts about apalutamide.
Źródło:
OncoReview; 2021, 11, 3; 85-88
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Apalutamide as a new option for postponing metastatic disease in hormone -resistant patients with biochemical recurrence in prostate cancer
Autorzy:
Dąbek, Bartosz
Powiązania:
https://bibliotekanauki.pl/articles/22676825.pdf
Data publikacji:
2023-04-04
Wydawca:
Medical Education
Tematy:
non-metastatic castration-resistant prostate cancer
apalutamide
Opis:
Treatment of non-metastatic castration-resistant prostate cancer is a radically new option for cancer patients. Novel anti-hormonal therapy not only improves metastasis free survival but overall survival times and positively impacts quality of life. This case shows how apalutamide lowered tPSA level and postponed metastatic disease.
Źródło:
OncoReview; 2023, 13, 1; 24-26
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Apalutamide as a therapeutic option in case of local failure in the nmCRPC
Autorzy:
Stankiewicz, Magdalena
Powiązania:
https://bibliotekanauki.pl/articles/22676730.pdf
Data publikacji:
2023-04-01
Wydawca:
Medical Education
Tematy:
prostate cancer
castration resistance
apalutamide
Opis:
Apalutamide is a non-steroidal selective androgen receptor inhibitor approved for the treatment of high-risk non-metastatic castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer. The paper describes a case of a patient diagnosed with prostate cancer with a long-term course of the disease. The patient was diagnosed with a non-metastatic castration-resistant stage 18 years after primary treatment. Systemic treatment with apalutamide was recommended. Initially, the treatment was carried out as part of the extended access to apalutamide program and from March 2022 as part of the B.56 drug program. The study presents the effectiveness and safety of the therapy in a 12-month follow-up period and discusses controversial aspects of the patient's previous treatments.
Źródło:
OncoReview; 2023, 13, 1; 13-19
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Apalutamide in the treatment of a patient with non-metastatic castration-resistant prostate cancer
Autorzy:
Dziura, Robert
Powiązania:
https://bibliotekanauki.pl/articles/22676763.pdf
Data publikacji:
2023-03-31
Wydawca:
Medical Education
Tematy:
prostate cancer
castration-resistant
androgen receptor inhibitor
Opis:
The treatment of patients with prostate cancer, who do not qualify for the radical therapy is based on the use of surgical or pharmacological castration methods. The effectiveness of the so-called androgen deprivation tends to decrease over time. Even in the absence of distant metastases on imaging studies, the resistance for the hormonal castration may be developed. At this moment, the use of new generation androgen receptor inhibitors may reduce the risk of metastases or death. The paper presents a case report of a patient with prostate cancer without distant metastases who started therapy with apalutamide at the moment of developing re-sistance to the pharmacological castration.
Źródło:
OncoReview; 2023, 13, 1; 20-23
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Apalutamide treatment of locally advanced prostate cancer
Autorzy:
Palasik, Maria
Powiązania:
https://bibliotekanauki.pl/articles/22676859.pdf
Data publikacji:
2023-03-31
Wydawca:
Medical Education
Tematy:
prostate cancer
castration resistance
hormonotherapy
apalutamide
Opis:
Prostate cancer is most commonly diagnosed cancer in men. The choice of treatment method depends on many factors: the patient’s age, other patient’s diseases, psychophysical status and expected survival time. Hormonotherapy plays very important role in patients with no possible radical treatment. New therapies apply in patients with castration-resistant metastatic prostate cancer. First registered drug in patients with biochemical progression without metastases is apalutamide.
Źródło:
OncoReview; 2023, 13, 1; 31-32
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Cardiovascular complications during the treatment of castration-resistant prostate cancer with the use of modern antiandrogens: abiraterone acetate and enzalutamide
Autorzy:
Grabysa, Radosław
Chmielewska, Agnieszka
Powiązania:
https://bibliotekanauki.pl/articles/2047222.pdf
Data publikacji:
2021-09-13
Wydawca:
Medical Education
Tematy:
abiraterone acetate
enzalutamide
castration resistant prostate cancer
cardiovascular
Opis:
Modern antiandrogens: abiraterone acetate (inhibitor of CYP17 cytochrome) and enzalutamide (irreversible inhibitor of androgen receptor) are the drugs that are increasingly often administered in treatment of castration-resistant prostate cancer. Despite their clinical efficacy, especially in terms of prolonged survival and improved quality of life of patients, they pose of problem for a practicing oncologist such as possible cardiovascular complications (particularly arterial hypertension), which may lead to the cessation of this form of therapy. This article provides a brief overview of the mechanisms responsible for the above complications, including practical recommendations in the event such complications arise. A simple scheme of action for control of cardiovascular risk factors has been presented, which can improve the prognosis in this population of patients.
Źródło:
OncoReview; 2021, 11, 3; 61-67
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Development of an automation system for iodine-125 brachytherapy seed encapsulated by Nd:YAG laser welding
Autorzy:
Somessari, S. L.
Feher, A.
Sprenger, F. E.
Rostelato, M. E. C. M.
da Costa, F. E.
Calvo, W. A. P.
Powiązania:
https://bibliotekanauki.pl/articles/147664.pdf
Data publikacji:
2011
Wydawca:
Instytut Chemii i Techniki Jądrowej
Tematy:
iodine-125 seeds
prostate cancer
brachytherapy
Nd:YAG laser welding
Opis:
The aim of this work is to develop an automation system for iodine-125 radioactive seed production by Nd:YAG laser welding, which has been used successfully in low dose rate (LDR) brachytherapy treatment. This small seed consists of a welded titanium capsule, with 0.8 mm in diameter and 4.5 mm in length, containing iodine-125 adsorbed onto a silver rod. The iodine-125 seeds are implanted into the human prostate to irradiate the tumor for cancer treatment. Nowadays, the Radiation Technology Center, at Institute for Nuclear and Energy Research, Săo Paulo, Brazil (IPEN-CNEN/SP) imports and distributes 36,000 iodine-125 seeds per year, for the clinics and hospitals in the country. However, the Brazilian market potential is now over 8,000 iodine-125 seeds per month. The local production of these iodine-125 radioactive sources became a priority for the Institute, in order to reduce the price and the problems of prostate cancer management. It will permit to spread their use to a larger number of patients in Brazil. On the other hand, the industrial automation plays an important role for iodine-125 seeds in order to increase the productivity, with high quality and assurance, avoiding human factors, implementing and operating with good manufacturing practices (GMP). The technology consists of appliance electronic and electro-mechanical parts and components to control machines and processes. The automation system technology for iodine-125 seed production developed in this work was mainly assembled employing a programmable logic controller (PLC), a stepper motor, an Nd:YAG laser welding machine and a supervisory. The statistical repeatability of correctly encapsulated sealed sources with this automation system is greater than 95 per cent.
Źródło:
Nukleonika; 2011, 56, 4; 369-374
0029-5922
1508-5791
Pojawia się w:
Nukleonika
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Diagnostyka i leczenie raka stercza u mężczyzn w podeszłym wieku
Diagnosis and treatment of prostate cancer in elderly men
Autorzy:
Skiba, Ryszard
Syryło, Tomasz
Ząbkowski, Tomasz
Powiązania:
https://bibliotekanauki.pl/articles/1033684.pdf
Data publikacji:
2015
Wydawca:
Medical Communications
Tematy:
CISR-G
Geriatric 8
diagnosis after the age of 70
prostate cancer
treatment after the age of 70
rak stercza
leczenie po 70. roku życia
diagnostyka po 70. roku życia
cisr-g
geriatric 8
Opis:
Prostate cancer is the most common malignant tumour in elderly men in Europe. The prevalence rate of prostate cancer is still increasing. This is related to higher costs of treatment. The biology of prostate cancer indicates that it belongs to a group of non-homogeneous tumours, including both neoplasms of small malignancy and clinical importance as well as neoplasms of high malignancy and great impact on the quality of life and lifespan. In the past years, many studies and meta-analyses on adjustment of diagnosis and treatment of prostate cancer to age and comorbidities have been conducted. The abovementioned studies show that not everyone with diagnosed prostate cancer should undergo radical treatment. In some groups of patients, complications of treatment may be greater than potential benefits, lead to the loss of the quality of life or even shorten life expectancy due to adverse effects. An individual choice of treatment is especially important in elderly men with multiple comorbidities. Therefore, the G8 and GISR questionnaires were established and assessed. Their aim is to evaluate the patient’s condition and choose an appropriate treatment method. The purpose of this study is to present the results of the above-mentioned meta-analyses and guidelines. This paper was prepared based on the EAU Guidelines from 2014.
Rak stercza jest najczęściej występującym nowotworem złośliwym u mężczyzn w podeszłym wieku w Europie. Częstość jego występowania w męskiej populacji europejskiej rośnie. Wiąże się to ze zwiększeniem nakładów finansowych na leczenie tej choroby. Biologia raka stercza wskazuje, że należy on do grupy niehomogennych raków – cechujących się zarówno małą złośliwością oraz istotnością kliniczną, jak i wysoką złośliwością oraz istotnym wpływem na jakość i długość życia. W ostatnich latach przeprowadzono wiele badań i metaanaliz mających na celu dostosowanie diagnostyki oraz leczenia raka stercza do wieku i chorób współistniejących. Badania te wskazują, że nie wszyscy chorzy z rozpoznanym rakiem stercza powinni być poddawani radykalnej terapii. W niektórych grupach pacjentów powikłania leczenia mogą przewyższać potencjalne korzyści, prowadzić do utraty jakości życia, a nawet skracać przewidywaną jego długość, z uwagi na działania niepożądane. Szczególnie istotny jest indywidualny dobór terapii dla chorych w wieku podeszłym z licznymi obciążeniami dodatkowymi. Wobec powyższego opracowano i oceniono w praktyce klinicznej kwestionariusze GISR oraz G8, mające na celu ewaluację stanu zdrowia chorego, a także dobranie odpowiedniej metody leczenia. W poniższym opracowaniu zaprezentowano wyniki wymienionych wyżej badań oraz zalecanych schematów postępowania. Pracę tę przygotowano, opierając się na edycji EAU Guidelines z 2014 roku.
Źródło:
Pediatria i Medycyna Rodzinna; 2015, 11, 1; 39-47
1734-1531
2451-0742
Pojawia się w:
Pediatria i Medycyna Rodzinna
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Gene-occupation interactions: a review of the literature on bladder and prostate cancer
Autorzy:
Wieczorek, Edyta
Wolniakowska, Anna
Roszak, Joanna
Rodrigues, Robim M.
Vanhaecke, Tamara
Reszka, Edyta
Powiązania:
https://bibliotekanauki.pl/articles/2203023.pdf
Data publikacji:
2023-05-19
Wydawca:
Instytut Medycyny Pracy im. prof. dra Jerzego Nofera w Łodzi
Tematy:
bladder cancer
gene
genetic susceptibility
occupational exposure
prostate cancer
workplace
Opis:
Bladder cancer (BCa) and prostate cancer (PCa) are genitourinary cancers which constitute significant health problems in men and in which environmental factors play an important role. Understanding the genetic susceptibility to BCa or PCa and occupational exposure is paramount to improving cancer prevention and early detection. The aim of this review article was to address the scientific evidence on the genetic risk factors and occupational exposure associated with the occurrence of BCa and PCa. The authors identified relevant original articles that have been published between 1994 and 2023. Variations of the following search terms: “gene” and “occupational” combined with one of the following terms: “bladder cancer” or “prostate cancer” were applied for the search purpose. The authors found 342 publications of which 50 population studies met their requirements for gene-occupation interactions. In total, 34 full-text manuscripts were about BCa and 16 about PCa. These research examines the genes involved in detoxification processes of xenobiotics (glutathione S-transferase, N-acetyltransferase, cytochrome P450, UDP-glucuronosyltransferase), oxidative stress (glutathione peroxidase 1, manganese superoxide dismutase, catalase), altering DNA repair capacity (X-ray repair cross-complementing 1, base excision repair, nucleotide excision repair), tumour suppression (TP53 gene), and vitamin D pathway (vitamin D receptor gene). The role of genetic factors in the occupational exposure has not been conclusively established, but it appears the possibility of genetic involvement. Determination of environmentally responsive genes provides important mechanistic implications for the etiology of occupational cancers, and valuable input in occupational exposure limits set by taking genetic susceptibility into account. More genetic research is needed to corroborate these findings and assess their significance in the workplace. Med Pr. 2023;74(2):127–44
Źródło:
Medycyna Pracy; 2023, 74, 2; 127-144
0465-5893
2353-1339
Pojawia się w:
Medycyna Pracy
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Inability of shear-wave elastography to distinguish malignant from benign prostate tissue – a comparison of biopsy, whole-mount sectioning and shear-wave elastography
Elastografia fali poprzecznej nie pozwala na odróżnienie zmian w sterczu o charakterze złośliwym i łagodnym – analiza porównawcza wyników biopsji, badania histopatologicznego i elastografii
Autorzy:
Porsch, Markus
Görner, Claudia
Wendler, Johann Jakob
Liehr, Uwe-Bernd
Lux, Anke
Siedentopf, Sandra
Schostak, Martin
Pech, Maciej
Powiązania:
https://bibliotekanauki.pl/articles/1051242.pdf
Data publikacji:
2016
Wydawca:
Medical Communications
Tematy:
biopsja stercza
elastografia
elastography
fala poprzeczna
prostate biopsy
prostate cancer
rak stercza
shear wave
ultrasonografia
ultrasound
Opis:
Aim: This study was designed to assess the possible usefulness of shear-wave elastography in differentiating between benign and malignant tissue in prostate neoplasia. Patients and methods: A total of 120 prostate tissue samples were obtained from 10 patients treated by radical prostatectomy and investigated pre-operatively by ultrasound elastography followed by directed biopsy. After resection, whole-mount sectioning and histological examination was performed. The predictions based on shear-wave elastography were compared with biopsy and histological results. Results: The comparison between the results of shear-wave elastography and those of biopsy was performed by receiver operating characteristic analysis, which suggested an optimum cut-off tissue elasticity value of 50 kPa, in agreement with earlier studies aimed at distinguishing between benign and malignant tissue. However, the diagnostic selectivity (and thus the diagnostic power) was poor (area under the curve 0.527, which hardly differs from the value of 0.500 that would correspond to a complete lack of predictive power); furthermore, application of this cut-off value to the samples led to a sensitivity of only 74% and a specificity of only 43%. An analogous comparison between the results of shear-wave elastography and those of whole-mount histology, which itself is more reliable than biopsy, gave an even poorer diagnostic selectivity (sensitivity of 62%, specificity of 35%). Meaningful association with Gleason score was not found for D’Amico risk groups (p = 0.35). Conclusions: The (negative) findings of this investigation add to the dissonance among results of studies investigating the possible value of shear-wave elastography as a diagnostic tool to identify malignant neoplasia. There is a clear need for further research to elucidate the diversity of study results and to identify the usefulness, if any, of the method in question.
Cel pracy: Celem badania była ocena użyteczności elastografii fali poprzecznej w odróżnianiu zmian złośliwych stercza od łagodnych. Pacjenci i metody: W sumie uzyskano 120 próbek tkanek gruczołu krokowego od 10 pacjentów, u których przeprowadzono zabieg radykalnej prostatektomii, poprzedzony biopsją i badaniem elastograficznym. Po resekcji wykonano badanie histopatologiczne pełnych przekrojów poprzecznych preparatu. Przypuszczenia wysunięte po elastografii fali poprzecznej porównano z wynikami biopsji i badania histopatologicznego. Wyniki: Wyniki badania elastograficznego i biopsji porównano za pomocą analizy wskaźnika zmian, w której określono optymalną wartość odcięcia dla sztywności tkanek na poziomie 50 kPa, co jest zgodne z wcześniejszymi badaniami prowadzonymi w celu rozróżnienia zmian złośliwych oraz łagodnych. Jednak selektywność diagnostyczna (a tym samym moc diagnostyczna) metody okazała się niska (pole powierzchni pod krzywą wyniosło 0,527, co tylko nieznacznie różni się od wartości 0,500, odpowiadającej zupełnemu brakowi mocy predykcyjnej). Ponadto czułość i swoistość po zastosowaniu tej wartości odcięcia wyniosły odpowiednio 74% i 43%. Analogiczna analiza, porównująca wyniki badania elastograficznego i histologicznego, które samo w sobie jest bardziej miarodajne niż biopsja, wykazała jeszcze niższą selektywność diagnostyczną metody (czułość 62%, swoistość 35%). Nie zaobserwowano znaczącej korelacji między stopniem w skali Gleasona i grupami ryzyka określonymi przez D’Amico (p = 0,35). Wnioski: Powyższe (negatywne) obserwacje zwiększają dysonans między dostępnymi wynikami badań dotyczących potencjalnej wartości diagnostycznej elastografii fali poprzecznej w nowotworach złośliwych. Konieczne są więc dalsze badania, wyjaśniające rozbieżność dotychczasowych obserwacji, aby jednoznacznie określić przydatność opisywanej metody (bądź potwierdzić jej brak).
Źródło:
Journal of Ultrasonography; 2016, 16, 67; 348-358
2451-070X
Pojawia się w:
Journal of Ultrasonography
Dostawca treści:
Biblioteka Nauki
Artykuł
Wyświetlanie 1-15 z 51

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies